Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2220021
Max Phase: Preclinical
Molecular Formula: C18H36N4O10
Molecular Weight: 468.50
Molecule Type: Small molecule
Associated Items:
ID: ALA2220021
Max Phase: Preclinical
Molecular Formula: C18H36N4O10
Molecular Weight: 468.50
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: C[C@@H](O)[C@H]1O[C@H](O[C@H]2[C@H](O[C@@H]3O[C@H](CN)[C@@H](O)[C@H]3O)[C@@H](O)[C@H](N)C[C@@H]2N)[C@H](N)[C@@H](O)[C@@H]1O
Standard InChI: InChI=1S/C18H36N4O10/c1-4(23)14-12(27)11(26)8(22)17(30-14)31-15-6(21)2-5(20)9(24)16(15)32-18-13(28)10(25)7(3-19)29-18/h4-18,23-28H,2-3,19-22H2,1H3/t4-,5-,6+,7-,8-,9+,10-,11-,12+,13-,14-,15-,16-,17-,18+/m1/s1
Standard InChI Key: MEPDGBXIGMERFR-MNNDRVTFSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 468.50 | Molecular Weight (Monoisotopic): 468.2431 | AlogP: -6.26 | #Rotatable Bonds: 6 |
Polar Surface Area: 262.38 | Molecular Species: BASE | HBA: 14 | HBD: 10 |
#RO5 Violations: 2 | HBA (Lipinski): 14 | HBD (Lipinski): 14 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 12.17 | CX Basic pKa: 9.59 | CX LogP: -6.01 | CX LogD: -10.86 |
Aromatic Rings: 0 | Heavy Atoms: 32 | QED Weighted: 0.17 | Np Likeness Score: 1.61 |
1. Guchhait S, Khononov A, Pieńko T, Belakhov V, Baasov T.. (2023) Balancing Nonsense Mutation Readthrough and Toxicity of Designer Aminoglycosides for Treatment of Genetic Diseases., 14 (6): [PMID:37312846] [10.1021/acsmedchemlett.3c00089] |
Source(1):